Regulatory Thresholds and Qualification

Impurity Profiling and Forced Degradation

Regulatory Thresholds and Qualification

International Council for Harmonisation guidelines Q3A and Q3B establish a tiered system of thresholds governing the regulatory handling of impurities in new drug substances and new drug products respectively. The reporting threshold defines the concentration above which an impurity must be reported in analytical results and specifications; the identification threshold defines the concentration above which the structural identity of an impurity must be established, typically through spectroscopic or mass spectrometric characterisation; and the qualification threshold defines the concentration above which the safety of the impurity must be demonstrated through toxicological data or documented biological safety justification. These thresholds are expressed as a function of the maximum daily dose of the drug product, reflecting the principle that impurity control should be proportionate to patient exposure.

Regulatory thresholds are the impurity limits established by the International Council for Harmonisation (ICH) to determine when an impurity should be reported, identified, and qualified in pharmaceutical drug substances and drug products. These limits are based on the Maximum Daily Dose (MDD) of the drug to ensure patient safety and product quality.

Regulatory thresholds help to:

  • Ensure patient safety.
  • Control impurities in pharmaceutical products.
  • Meet ICH and regulatory requirements.
  • Maintain consistent product quality.
  • Support regulatory approval of new medicines.

1. Reporting Threshold

The reporting threshold is the impurity level above which the impurity must be reported in analytical results and product specifications.

Purpose

  • Record impurities present in the product.
  • Include impurity levels in quality control reports.

2. Identification Threshold

The identification threshold is the impurity level above which the chemical structure of the impurity must be identified.

Purpose

  • Determine the source of the impurity.
  • Evaluate whether the impurity could affect product quality or safety.

3. Qualification Threshold

The qualification threshold is the impurity level above which the biological safety of the impurity must be demonstrated through toxicological studies or scientific evidence.

Purpose

  • Confirm that the impurity is safe for patients.
  • Ensure regulatory compliance.

The impurity limits depend on the Maximum Daily Dose (MDD) of the drug.

General principle:

  • Higher daily dose → Lower acceptable impurity limit
  • Lower daily dose → Higher acceptable impurity limit

This approach helps minimize patient exposure to impurities.

ICH Q3A(R2) — Impurities in New Drug Substances

  • Provides limits for reporting, identification, and qualification of impurities in APIs.
  • Applies during drug substance development.

ICH Q3B(R2) — Impurities in New Drug Products

  • Covers impurities present in finished pharmaceutical products.
  • Establishes impurity limits for drug products.

ICH Q3C(R9) — Residual Solvents

  • Controls the amount of organic solvents remaining after manufacturing.
  • Solvents are classified according to their toxicity.

ICH Q3D(R2) — Elemental Impurities

Controls metal impurities such as:

  • Lead (Pb)
  • Arsenic (As)
  • Cadmium (Cd)
  • Mercury (Hg)

These impurities are controlled to ensure patient safety.

ICH M7(R2) — Mutagenic Impurities

  • Controls DNA-reactive (mutagenic) impurities that may increase the risk of cancer.
  • Uses the Threshold of Toxicological Concern (TTC) to establish acceptable limits.

To comply with regulatory requirements, pharmaceutical companies should:

  • Perform complete impurity profiling.
  • Develop validated analytical methods.
  • Control impurities using appropriate specifications.
  • Justify impurities above qualification limits with safety data.
  • Maintain complete documentation for regulatory submission.

Regulatory thresholds help ensure that impurities in pharmaceutical products are properly reported, identified, and qualified based on their potential risk to patients. Compliance with ICH Q3A, Q3B, Q3C, Q3D, and M7 guidelines ensures product quality, patient safety, and successful regulatory approval.

  • Reporting Threshold: Report the impurity.
  • Identification Threshold: Identify the impurity.
  • Qualification Threshold: Prove the impurity is safe.
  • Maximum Daily Dose (MDD): Determines acceptable impurity limits.
  • ICH Guidelines: Q3A, Q3B, Q3C, Q3D, and M7 provide global standards for impurity control.

Key Takeaway

Regulatory thresholds are impurity limits established by ICH guidelines to ensure that pharmaceutical impurities are properly reported, identified, and qualified according to their concentration and patient exposure. Following these guidelines helps maintain drug quality, ensures patient safety, and supports regulatory approval of pharmaceutical products.

The impurity thresholds and reporting expectations established in International Council for Harmonisation Q3A, Q3B, Q3C, Q3D, and M7 collectively define the regulatory expectations against which impurity specifications in drug substance and drug product dossiers are evaluated during marketing authorisation review.